Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2018 /
Front-line therapy of DIPG using IDO inhibitor with radiation and chemotherapy

14th - 18th Apr 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 25.04.18
Views: 10586

Dr Theodore Johnson - Georgia Cancer Center, Augusta, USA

Dr Johnson speaks with ecancer at AACR 2018 about results from brain cancer patients treated with IDO inhibitor indoximod alongside chemotherapy and radiation.

He describes the cohort of diffuse intrinsic pontine glioma (DIPG) patients, and the tolerability of the trial triplet therapy.

Dr Johnson notes that lower-dose, restricted-field radiotherapy may be beneficial with indoximod in relapse cases.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation